Litcius/Paper detail

Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study

Xingzhi Li, Xiaobo Wang, Tao Bai, Jie Chen, Shaolong Lu, Tao Wei, Zhihong Tang, Guilin Zhao, Huaze Lu, Le‐Qun Li, Feixiang Wu

2023Digestive and Liver Disease13 citationsDOI

Topics & Concepts

MedicineLenvatinibHepatocellular carcinomaPropensity score matchingIncidence (geometry)Transcatheter arterial chemoembolizationInternal medicineObservational studyGastroenterologySurgeryUrologyOncologySorafenibOpticsPhysicsHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesOrgan Transplantation Techniques and Outcomes
Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study | Litcius